ChemoCentryx Appoints Anne-Marie S. Duliege, M.D., M.S. to Chief Strategic Development Role and Head of Immuno-Oncology

By: via Benzinga
ChemoCentryx, Inc., (Nasdaq: CCXI), a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.